Tumorigenesis Suppressor Pdcd4 Down-Regulates Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 Expression To Suppress Colon Carcinoma Cell Invasion

ABSTRACT Programmed cell death 4 (Pdcd4) suppresses neoplastic transformation by inhibiting the activation of c-Jun and consequently AP-1-dependent transcription. We report that Pdcd4 blocks c-Jun activation by inhibiting the expression of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1)/hematopoietic progenitor kinase 1, a kinase upstream of Jun N-terminal kinase (JNK). cDNA microarray analysis of Pdcd4-overexpressing RKO human colon carcinoma cells revealed MAP4K1 as the sole target of Pdcd4 on the JNK activation pathway. Cotransfection of a MAP4K1 promoter-reporter with Pdcd4 demonstrated inhibition of transcription from the MAP4K1 promoter. Ectopic expression of Pdcd4 in metastatic RKO cells suppressed invasion. MAP4K1 activity is functionally significant in invasion, as overexpression of a dominant negative MAP4K1 (dnMAP4K1) mutant in RKO cells inhibited not only c-Jun activation but also invasion. Overexpression of a MAP4K1 cDNA in Pdcd4-transfected cells rescued the kinase activity of JNK. Thus, Pdcd4 suppresses tumor progression in human colon carcinoma cells by the novel mechanism of down-regulating MAP4K1 transcription, with consequent inhibition of c-Jun activation and AP-1-dependent transcription.

[1]  C. Proud.  Turned on by insulin , 1994, Nature.

[2]  C. Proud.  Translation. Turned on by insulin. , 1994, Nature.

[3]  B. Ozanne,et al.  Fos-transformation activates genes associated with invasion. , 1994, Oncogene.

[4]  T. Honjo,et al.  Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. , 1995, Gene.

[5]  L. Matrisian,et al.  Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. , 1996, Enzyme & protein.

[6]  T. Pawson,et al.  HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway. , 1996, The EMBO journal.

[7]  M. C. Hu,et al.  Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade. , 1996, Genes & development.

[8]  H. Kizaki,et al.  Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors. , 1996, Biochemical and biophysical research communications.

[9]  S. Schreiber,et al.  A Signaling Pathway to Translational Control , 1996, Cell.

[10]  B. Ozanne,et al.  AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44 , 1997, Molecular and cellular biology.

[11]  G. Stamp,et al.  Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma , 1997, The Journal of pathology.

[12]  William C. Parks,et al.  The Activity of Collagenase-1 Is Required for Keratinocyte Migration on a Type I Collagen Matrix , 1997, The Journal of cell biology.

[13]  C. Brinckerhoff,et al.  The AP-1 site and MMP gene regulation: what is all the fuss about? , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[14]  D. Taub,et al.  A dominant negative mutant of jun blocking 12‐O‐tetradecanoylphorbol‐13‐acetate–induced invasion in mouse keratinocytes , 1997, Molecular carcinogenesis.

[15]  E. Goldsmith,et al.  A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation , 1998, Current Biology.

[16]  S. Yuspa,et al.  The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. , 1998, Journal of dermatological science.

[17]  L. Azzoni,et al.  Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. , 1998, Journal of immunology.

[18]  N. Colburn,et al.  Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[20]  T. Tan,et al.  Hematopoietic Progenitor Kinase 1 Is a Component of Transforming Growth Factor β-induced c-Jun N-terminal Kinase Signaling Cascade* , 1999, The Journal of Biological Chemistry.

[21]  A. Albini,et al.  c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. De Benedetti,et al.  eIF4E expression in tumors: its possible role in progression of malignancies. , 1999, The international journal of biochemistry & cell biology.

[23]  S. Feller,et al.  Interaction of Hematopoietic Progenitor Kinase 1 with Adapter Proteins Crk and CrkL Leads to Synergistic Activation of c-Jun N-Terminal Kinase , 1999, Molecular and Cellular Biology.

[24]  J. Winnie,et al.  Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. , 2000, European journal of cancer.

[25]  T. Kislinger,et al.  Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.

[26]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[27]  S. Curran,et al.  Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. , 2000, European journal of cancer.

[28]  M. Cobb,et al.  HPK1 is activated by lymphocyte antigen receptors and negatively regulates AP-1. , 2000, Immunity.

[29]  Arthur Weiss,et al.  Hematopoietic Progenitor Kinase 1 Associates Physically and Functionally with the Adaptor Proteins B Cell Linker Protein and SLP-76 in Lymphocytes* , 2001, The Journal of Biological Chemistry.

[30]  P. Ling,et al.  Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes , 2001, Oncogene.

[31]  R. Reeves,et al.  Architectural Transcription Factor HMGI(Y) Promotes Tumor Progression and Mesenchymal Transition of Human Epithelial Cells , 2001, Molecular and Cellular Biology.

[32]  M. C. Hu,et al.  Involvement of Hematopoietic Progenitor Kinase 1 in T Cell Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[33]  N. Colburn,et al.  A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation , 2001, Oncogene.

[34]  E. Shin,et al.  c-Jun N-terminal kinase is involved in motility of endothelial cell , 2001, Experimental & Molecular Medicine.

[35]  R. DuBois,et al.  Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor , 2001, Oncogene.

[36]  D. Boyd,et al.  An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. , 2002, Biochimica et biophysica acta.

[37]  R. Carmody,et al.  DUG is a novel homologue of translation initiation factor 4G that binds eIF4A. , 2002, Biochemical and biophysical research communications.

[38]  W. Park,et al.  Up-regulation of PDCD4 in senescent human diploid fibroblasts. , 2002, Biochemical and biophysical research communications.

[39]  K. Anderson,et al.  Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays , 2002, Oncogene.

[40]  N. Sonenberg,et al.  The Transformation Suppressor Pdcd4 Is a Novel Eukaryotic Translation Initiation Factor 4A Binding Protein That Inhibits Translation , 2003, Molecular and Cellular Biology.

[41]  Jennifer L. Knies,et al.  Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation , 2003, Oncogene.

[42]  P. O'dwyer,et al.  Role of Jun and Jun kinase in resistance of cancer cells to therapy. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[43]  Iver Petersen,et al.  Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis , 2003, The Journal of pathology.

[44]  N. Colburn,et al.  Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model. , 2003, Molecular cancer research : MCR.

[45]  Nahum Sonenberg,et al.  A Novel Function of the MA-3 Domains in Transformation and Translation Suppressor Pdcd4 Is Essential for Its Binding to Eukaryotic Translation Initiation Factor 4A , 2004, Molecular and Cellular Biology.

[46]  H. Samuels,et al.  Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis , 2004, Oncogene.

[47]  N. Colburn,et al.  Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. , 2004, Molecular cancer therapeutics.

[48]  K. Klempnauer,et al.  Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun , 2004, Oncogene.

[49]  A. Hasilik,et al.  Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II , 2004, Molecular and Cellular Endocrinology.

[50]  R. Arnold,et al.  Programmed Cell Death Protein 4 (PDCD4) Acts As a Tumor Suppressor in Neuroendocrine Tumor Cells , 2004, Annals of the New York Academy of Sciences.

[51]  N. Colburn,et al.  Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation , 2004, Oncogene.

[52]  N. Colburn,et al.  Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. , 2005, Cancer research.

[53]  T. Tan,et al.  Functional interactions of HPK1 with adaptor proteins , 2005, Journal of cellular biochemistry.

[54]  A. Wlodawer,et al.  Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI. , 2005, RNA.